NDLI: Prostate-specific antigen screening: pro.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Loeb, Stacy Catalona, William J.
Description	Country affiliation: United States Author Affiliation: Loeb S ( Brady Urological Institute, Johns Hopkins Medical Institutions, 600 N. Wolfe Street, Baltimore, MD 21231, USA. stacyloeb@gmail.com)
Abstract	PURPOSE OF REVIEW: Prostate cancer is the most common noncutaneous malignancy among men in the USA and is most frequently diagnosed through prostate-specific antigen (PSA)-based screening. Nevertheless, PSA testing has become increasingly controversial. In this review, we will present the evidence supporting the role of PSA in prostate cancer screening. RECENT FINDINGS: Numerous studies have shown that the risk of current and future prostate cancer is directly related to the serum PSA level. Moreover, increasing PSA levels predict a greater risk of adverse pathologic features and worse disease-specific survival. Substantial epidemiologic evidence has suggested a reduction in advanced disease and improvements in prostate cancer survival rates since the introduction of PSA-based screening. Recently, evidence from a randomized trial further validated that PSA testing reduces both metastatic disease and prostate cancer-specific mortality. SUMMARY: PSA is a valid marker for prostate cancer and its aggressiveness. Level 1 evidence is now available that PSA-based screening reduces both the rate of metastatic disease and prostate cancer-specific mortality.
File Format	HTM / HTML
ISSN	09630643
e-ISSN	14736586
DOI	10.1097/MOU.0b013e3283384047
Journal	Current Opinion in Urology
Issue Number	3
Volume Number	20
Language	English
Publisher	Lippincott Williams & Wilkins
Publisher Date	2010-05-01
Publisher Place	United States
Access Restriction	Open
Subject Keyword	Discipline Urology Prostate-specific Antigen Blood Prostatic Neoplasms Diagnosis Tumor Markers, Biological Mass Screening Prognosis Epidemiology Risk Factors Research Support, N.i.h., Extramural
Content Type	Text
Resource Type	Article
Subject	Urology

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Prostate kallikrein markers in diagnosis, risk stratification and prognosis.

Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer.

Blood and tissue biomarkers in prostate cancer: state of the art.

Prostate-specific antigen screening for prostate cancer: benefits for patients with highly aggressive prostate cancer.

Risk stratification of prostate cancer in the modern era.

Serum markers in prostate cancer detection.

Prostate cancer in young men: an important clinical entity.

Prostate cancer: estimating the benefits of PSA screening.

Biomarkers for benign prostatic hyperplasia progression.

Prostate-specific antigen screening: pro.

Similar Documents

Prostate kallikrein markers in diagnosis, risk stratification and prognosis.

Early prostate-specific antigen changes and the diagnosis and prognosis of prostate cancer.

Blood and tissue biomarkers in prostate cancer: state of the art.

Prostate-specific antigen screening for prostate cancer: benefits for patients with highly aggressive prostate cancer.

Risk stratification of prostate cancer in the modern era.

Serum markers in prostate cancer detection.

Prostate cancer in young men: an important clinical entity.

Prostate cancer: estimating the benefits of PSA screening.

Biomarkers for benign prostatic hyperplasia progression.

Prostate-specific antigen screening: pro.